Mounjaro/Zepbound (tirzepatide) is a GLP1/GIP dual agonist (~2022.5% loss)

certificate of analysis available on request Research Applications Suitable Laboratory Uses for 5-Amino-1MQ NNMT enzyme inhibition assays IC50 determination, target engagement confirmation, and 1-MNA quantification NAD+ salvage pathway modulation studies nicotinamide flux, NMN and NAD+ pool measurement SAM/SAH methyl-donor pathway and epigenetic methylation capacity research Adipocyte biology lipogenesis, adipocyte differentiation, fat mass, and lipid storage pathway studies SIRT1 and SIRT3 activation and insulin sensitivity pathway investigations Mitochondrial function and energy expenditure pathway research Skeletal muscle physiology muscle function, sarcopenia pathway, and mitophagy-related studies NNMT-overexpressing cancer cell line studies anti-proliferative and apoptotic pathway research Gut microbiome modulation research in diet-induced obesity models Cardiovascular metabolic pathway studies homocysteine, NF-B, STAT3, redox signalling Comparative NNMT inhibitor research 5-Amino-1MQ vs

The result is meaningful weight loss and better blood sugar, with proven cardiovascular benefit in obese patients on top of that [4]
CHO-K1 cells (ATCC) were stably transfected with a human GLP-1R expression plasmid and maintained in Dulbeccos Modified Eagle Medium, 10% fetal bovine serum, 500 g/mL geneticin and 400 g/mL hygromycin B
Tirzepatides boxed warning and labeled warnings exist because it completed the review that produces such labeling
Diabetes Care 48 (7), 10571082